Food Allergy
Clinical Snapshot
Food allergy is an immune-mediated, IgE-driven (Type I) hypersensitivity reaction to a specific food protein: the immune system misidentifies a harmless dietary protein as a threat, and on a later exposure, allergen-specific IgE already bound to mast cells and basophils cross-links and triggers the release of histamine and other mediators, producing symptoms within minutes to about 2 hours of ingestion.[1] This is a fundamentally different process from a food intolerance (e.g., lactose intolerance) or a food-related side effect, neither of which involves the immune system and neither of which is reproducibly triggered by trace amounts the way a true allergy can be.
Food allergy affects roughly 6.7% of Canadians overall by self-report — 7.1% of children and 6.6% of adults — making it a genuinely common condition every community pharmacist will encounter regularly, not a rare one.[2] International reviews describe an "impression" of rising prevalence over recent decades, with some populations now reporting rates as high as roughly 10%.[1]
This platform's Anaphylaxis chapter covers the acute emergency protocol for a severe allergic reaction of any cause — diagnostic criteria, weight-based epinephrine dosing, positioning, adjuncts, and the discharge checklist — in full depth, and this chapter does not repeat that content. This chapter's focus is the broader, longer-term picture that determines whether a patient with food allergy actually avoids that emergency in the first place: accurate diagnosis, natural history and prognosis, day-to-day avoidance strategy, allergen-labelling literacy, oral immunotherapy and other emerging disease-modifying options, and the counseling that keeps an anaphylaxis action plan effective between reactions.
Recognize the Condition
Pathophysiology, in brief
IgE-mediated food allergy begins with sensitization: on an initial exposure, the immune system generates allergen-specific IgE antibodies to a specific food protein, which then bind to receptors on mast cells and basophils throughout the body. On a subsequent exposure, the allergen cross-links this bound IgE, triggering degranulation and the release of histamine and other inflammatory mediators — the same final common pathway underlying anaphylaxis from any cause (see the Anaphylaxis chapter for the complete mechanism and organ-by-organ recognition of an acute reaction).[1]
The 11 Canadian priority food allergens
Health Canada's Food and Drug Regulations designate 11 specific allergen sources as priority allergens, reflecting the foods responsible for the large majority of serious food-allergic reactions in Canada. When intentionally present as an ingredient, each must be declared on a pre-packaged food label in plain, common language — either directly in the ingredient list or in a separate "Contains" statement immediately following it — even when the ingredient list already names it in a technical or scientific term (e.g., "casein" must still trigger a plain-language "Contains: Milk" declaration).[3]
| Priority allergen | Notes |
|---|---|
| Peanut | A legume, not a tree nut; a leading cause of severe reactions and the allergen most studied for oral immunotherapy and omalizumab. |
| Tree nuts | Includes almond, Brazil nut, cashew, hazelnut, macadamia, pecan, pine nut, pistachio, and walnut — each is its own distinct allergen, though co-allergy is common. |
| Milk | Includes all mammalian milk sources; distinct from lactose intolerance, which is not an allergy (see Assessment & Diagnosis). |
| Egg | Both the white and the yolk; egg white generally carries the more clinically significant proteins. |
| Wheat and triticale | Distinct from celiac disease and non-coeliac gluten sensitivity, which are not IgE-mediated (see Assessment & Diagnosis). |
| Soy | A legume, biologically related to peanut but with clinically low cross-reactivity between the two. |
| Sesame | Canada's 11th priority allergen, with mandatory labelling in effect since 2022 — the most recently added. |
| Fish | Distinct from crustacean/mollusc allergy; a patient may be allergic to one group without the other. |
| Crustaceans and molluscs | Shrimp, crab, and lobster (crustaceans) and clams, mussels, oysters, and scallops (molluscs) are regulated as 2 related but distinct allergen groups. |
| Mustard | A common hidden ingredient in prepared sauces, dressings, and marinades. |
| Sulphites | Not a food-protein allergen in the IgE-mediated sense for most reactors, but regulated identically; mandatory declaration applies once total sulphites reach 10 parts per million or more. |
Precautionary "may contain" cross-contact statements are voluntary in Canada, not mandatory — a genuinely important, and commonly misunderstood, regulatory distinction from the mandatory "Contains" declaration above. A manufacturer may choose to add a "may contain" statement when unintended trace allergen presence cannot be fully ruled out despite good manufacturing practice, but nothing requires them to do so.[3] Teach patients that the absence of a "may contain" statement is not proof of safety (see Choose Initial Treatment).
Natural history — which food allergies are typically outgrown
Prognosis varies substantially by allergen, and this genuinely changes counseling and follow-up planning. Milk, egg, soy, and wheat allergy are the most likely to be outgrown in childhood: roughly 57% of infants with milk allergy and about 47% with egg allergy have outgrown it by 2 years of age, and soy allergy resolves in roughly 25% by age 4, 45% by age 6, and 69% by age 10.[4] Peanut, tree nut, fish, and shellfish allergy are far more likely to persist — one large population-based cohort found peanut allergy resolved in only about 29% of children by age 6, and the limited data available on tree nut allergy suggest an even lower resolution rate (roughly 9%).[4] Some recent data suggest milk and egg allergy, traditionally taught as reliably outgrown, may be persisting into young adulthood more often than previously assumed — an evolving area worth flagging honestly to patients and families rather than promising a fixed timeline.[4]
Risk Factors
Risk factors for developing a food allergy
- A personal history of atopic dermatitis (eczema), particularly early-onset, moderate-to-severe disease — the leading identified risk factor, thought to reflect allergen sensitization through a disrupted skin barrier.[4]
- A family history of any allergic disease (food allergy, asthma, allergic rhinitis, eczema) in a parent or sibling.
- An existing food allergy, asthma, or allergic rhinitis — allergic conditions cluster within the same patient.
- Delayed introduction of an allergenic food beyond the currently recommended window in infancy, and — once introduced — infrequent or inconsistent ongoing ingestion; current Canadian guidance emphasizes that regular ingestion after introduction, not introduction timing alone, is what appears to build and maintain tolerance.[5]
- Younger age — food allergy is more common in early childhood, consistent with the natural-history pattern above.
Risk factors associated with a more severe reaction
- Coexisting asthma, particularly when poorly controlled — a long-recognized and accepted risk factor for a more severe or fatal reaction (see Special Populations).
- Multiple confirmed food allergies.
- Adolescent and young-adult age, largely reflecting behaviour (see Special Populations) rather than a different underlying mechanism.
- A food allergen with a known association with more severe reactions, such as peanut or tree nut.
A 2022 rapid evidence review and meta-analysis found that individual risk markers — including a prior severe reaction, an asthma diagnosis, or the degree of allergen-specific IgE sensitization — do not reliably predict which specific patient will have a severe reaction on any given exposure.[6] In practice, this means reaction severity cannot be assumed from a patient's history: every patient with a confirmed food allergy needs full emergency preparedness (2 epinephrine autoinjectors, a written action plan, and demonstrated technique) regardless of how mild their past reactions have been.
Red Flags & Refer
Any sign of anaphylaxis after a known or suspected food exposure — hives or angioedema plus respiratory, cardiovascular, or persistent gastrointestinal involvement, or even a single severe respiratory or cardiovascular sign alone — requires this platform's Anaphylaxis protocol immediately: intramuscular epinephrine without delay and activation of emergency services. See the Anaphylaxis chapter for the complete diagnostic criteria and treatment algorithm; it is not repeated here.
- Any confirmed or strongly suspected IgE-mediated food allergy warrants allergist/immunology referral for diagnostic confirmation and a long-term management plan — this is not limited to patients who have already had anaphylaxis.
- Multiple confirmed food allergies, or a food allergy coexisting with asthma, mark a genuinely higher-risk patient who warrants more intensive action planning: closer allergist follow-up, a lower threshold to discuss disease-modifying options (oral immunotherapy, omalizumab), and specific attention to optimizing asthma control as part of overall risk reduction (see Special Populations).[6]
- A history of a prior severe reaction, or any prior reaction requiring more than 1 epinephrine dose, warrants allergist reassessment of the overall management plan.
- Signs suggesting a distinct non-IgE-mediated food-protein condition (e.g., profuse, delayed vomiting and lethargy after a specific food in an infant, suggesting FPIES; progressive feeding difficulty or reflux unresponsive to standard therapy, suggesting eosinophilic esophagitis) warrant referral for that specific evaluation rather than a standard IgE-allergy workup alone (see Assessment & Diagnosis).
Complications of an inadequately managed food allergy
- Recurrent severe reactions from accidental exposure — the central harm this entire chapter is built to prevent.
- Nutritional deficiency and impaired growth in a child, when an elimination diet is broader than the confirmed allergy actually requires and is not guided by a dietitian.
- Significant psychosocial burden: food-allergy-specific anxiety in patients and caregivers, social isolation, and a measurable impact on quality of life that is often underestimated by clinicians relative to families.
- Eosinophilic esophagitis, a distinct but related chronic atopic condition of the esophagus, occurs at higher rates in patients with IgE-mediated food allergy and should be considered when GI symptoms persist despite confirmed allergen avoidance.
Assessment & Diagnosis
The history is the foundation
For every patient with a suspected food allergy, a detailed history is the starting point and remains the single most important diagnostic input: which specific food, how much was eaten, how it was prepared, the time between ingestion and symptom onset, exactly what symptoms occurred, whether the reaction has been reproducible across more than 1 exposure, and any cofactors present (concurrent exercise, illness, or alcohol).[1]
Skin prick testing and serum-specific IgE — adjuncts, not a stand-alone diagnosis
Both skin prick testing and serum allergen-specific IgE measure sensitization — the presence of allergen-specific IgE — and not clinical allergy itself. Both have good sensitivity but limited specificity: a meaningful proportion of sensitized patients are positive on testing yet tolerate the food without any reaction at all, so a positive result in isolation, without a supporting clinical history, is not diagnostic and should not by itself lead to dietary elimination.[1] A negative result is more reassuring but still does not completely rule out allergy in a patient with an otherwise convincing history.[1]
Do not order unvalidated food-specific IgG testing or broad, unfocused allergen "panel" testing to diagnose a food allergy. CSACI's 2024 position statement is explicit that panel food testing has not been adequately validated as a screening tool, carries a considerable false-positive rate, and that the resulting false diagnoses drive unnecessary dietary restriction, added healthcare costs, and real psychosocial harm to patients and families; food-specific IgG testing specifically has no evidence supporting any role in diagnosing food allergy or intolerance.[7] Testing should always be targeted to specific foods implicated by the history, not ordered as an unfocused panel.
Oral food challenge — the diagnostic gold standard
An oral food challenge — feeding the food slowly, in gradually increasing amounts, under direct medical supervision with resuscitation equipment and epinephrine immediately available — remains the gold standard for confirming or ruling out an IgE-mediated food allergy, and is performed by an allergist/immunologist, not in a community or primary care setting.[1] It is used both to establish an initial diagnosis when the history and adjunct testing are inconclusive, and later to test for natural resolution in a patient whose allergy may have been outgrown (see Recognize the Condition and Special Populations).
Differential diagnosis
A substantial proportion of reported "food allergy" is not IgE-mediated food allergy at all. Consider:
- Food intolerance (e.g., lactose intolerance) — non-immune, dose-dependent, and typically limited to gastrointestinal symptoms; does not require allergen avoidance at trace levels or epinephrine preparedness.
- Food protein-induced enterocolitis syndrome (FPIES) — a non-IgE-mediated, cell-mediated reaction typically in infants, presenting with profuse, delayed (1-4 hour) vomiting and lethargy, sometimes with diarrhea, rather than the immediate urticaria/respiratory pattern of IgE-mediated allergy.
- Eosinophilic esophagitis (EoE) — a chronic, food- and aeroallergen-associated eosinophilic inflammatory condition of the esophagus presenting with dysphagia, food impaction, or reflux-like symptoms unresponsive to standard therapy; diagnosed by endoscopy and biopsy, not by IgE testing.
- Celiac disease — an immune-mediated but non-IgE reaction to gluten with a distinct diagnostic pathway (serology and duodenal biopsy); not prevented or detected by wheat-specific IgE testing.
- Oral allergy syndrome (pollen-food syndrome) — localized oral/perioral itching and mild swelling immediately after eating certain raw fruits or vegetables in a patient with pollen allergy, from cross-reactive, heat-labile proteins; usually mild and self-limited (cooking the food generally eliminates the reaction), though it still warrants individualized allergist assessment since a minority of patients experience more than local symptoms.
- Scombroid poisoning — histamine toxicity from improperly stored fish, which mimics an allergic reaction but is a toxin-mediated food-safety issue, not an immune one; classically affects multiple diners from the same meal simultaneously.
- Avoidant/restrictive food intake disorder (ARFID) or food aversion — a psychological or behavioural avoidance pattern, occasionally following a food-related medical event, without an underlying immune mechanism.
Treatment Targets
- Accurately distinguish true, IgE-mediated food allergy from intolerance, a non-immune reaction, or an over-attributed "allergy" — an accurate diagnosis, not simply broader avoidance, is the actual goal.
- Minimize the risk, frequency, and severity of accidental allergic reactions through effective, appropriately targeted avoidance.
- Ensure every patient and caregiver can recognize a reaction immediately and treat it without hesitation — a current epinephrine prescription (2 devices), a written action plan, and demonstrated technique.
- Support a nutritionally adequate, minimally restrictive avoidance diet, involving a registered dietitian for multiple or major allergens.
- Identify appropriate candidates for a disease-modifying option (oral immunotherapy or omalizumab) and support fully informed, shared decision-making about the real trade-offs involved.
- Reduce the psychosocial burden of living with food allergy and support normal participation in school, work, and social life.
- Put in place clear, workable accommodation across school, workplace, and travel settings.
- Periodically reassess for natural resolution, particularly in a child with milk, egg, soy, or wheat allergy, rather than defaulting to indefinite, unquestioned avoidance.
Choose Initial Treatment
Strict avoidance is the mainstay — everything else is an adjunct to it, not a replacement
Every confirmed food allergy strict avoidance of the confirmed allergen(s), built on accurate allergen-label reading and cross-contamination awareness, remains the foundation of management for essentially every patient.[8] A prescribed epinephrine autoinjector (2 devices), a written anaphylaxis action plan, and demonstrated technique complete the essential baseline — see the Anaphylaxis chapter for the complete acute-treatment protocol. Selected patients oral immunotherapy or, for confirmed multi-food allergy, omalizumab can raise the reaction threshold as an allergist-directed adjunct, but neither replaces avoidance, the action plan, or epinephrine access.[8][9]
Allergen-label reading — a core pharmacist counseling skill
Every priority allergen intentionally present must appear in plain language either in the ingredient list or in a "Contains" statement immediately after it, even when the ingredient list itself uses a technical term.[3] Teach patients to check every label, every time — even a previously "safe," repeatedly purchased product, since manufacturers can reformulate or change suppliers without any obvious change to the packaging. Precautionary "may contain" statements remain voluntary in Canada; counsel patients explicitly that the absence of a "may contain" statement is not a guarantee of safety, and that when genuine uncertainty remains, contacting the manufacturer directly is a reasonable and often necessary step before eating an ambiguous product.[3]
Cross-contamination versus cross-reactivity — a distinction worth teaching explicitly
Cross-contamination (cross-contact) is the physical transfer of allergen protein from one food to another via shared equipment, surfaces, utensils, or hands — a preparation and handling issue managed through kitchen practices: dedicated utensils/cutting boards for allergen-free preparation, thorough handwashing and surface cleaning between foods, and caution around shared fryers, grills, and buffet or bulk-bin settings where cross-contact is harder to control. Cross-reactivity is a distinct, immunologic phenomenon — an IgE reaction to a protein in a different food that structurally resembles the original allergen (e.g., some tree nut cross-reactivity, or the pollen-food cross-reactivity underlying oral allergy syndrome) — and is addressed through allergist-directed testing and counseling about which related foods genuinely need to be avoided, not through kitchen practice. Conflating the two leads either to unnecessarily broad avoidance or to under-appreciated real risk, so keep the distinction clear in counseling.
Oral immunotherapy (OIT) — an emerging, disease-modifying option, not a replacement for avoidance
Oral immunotherapy exposes a patient to gradually increasing doses of the actual allergenic food, under direct allergist supervision, with the goal of raising the amount of allergen the patient can tolerate before reacting.[8] CSACI's guidelines frame OIT as an evidence-based but still-emerging option, appropriate only within a program with specific training and resuscitation capability, and built on thorough, honest shared decision-making with the patient and family about its real risks and benefits.[8]
How OIT actually works
Patient selection
Generally a patient with a well-characterized IgE-mediated allergy to a single food or a limited number of foods, no poorly controlled asthma or other contraindication, and a patient/family genuinely able to commit to daily dosing, in-clinic visits, and the real possibility of a reaction during treatment.[8]
Protocol structure
An initial escalation day (several closely observed in-clinic doses in a single session), followed by a build-up phase (the dose increased at supervised clinic visits, typically every 1-2 weeks over several months), followed by a maintenance phase (a fixed daily dose continued at home, generally indefinitely).[8]
Desensitization vs. remission
Desensitization — a raised reaction threshold that depends on continued, regular dosing — is the outcome OIT reliably achieves. Sustained unresponsiveness (remission) — tolerating the food after a period completely off dosing — is a far less certain and less consistently demonstrated outcome, and cannot be promised to a patient considering OIT.[8]
Safety
Mild oral/GI symptoms (itching, abdominal discomfort) are common during updosing; genuine allergic reactions, including anaphylaxis, can occur at any point in the protocol — including during the maintenance phase — which is why OIT is only appropriate within a supervised allergy program with resuscitation capability, never as a self-directed or unsupervised process.[8]
OIT is not a guaranteed cure. It desensitizes and can meaningfully reduce reaction severity at a given exposure, but ongoing maintenance dosing is generally required indefinitely to sustain that protection, and interrupting maintenance dosing can result in a real loss of protection over time — a patient on OIT still needs an epinephrine prescription, a written action plan, and continued avoidance of any food not specifically part of their protocol.[8]
Omalizumab — a newer biologic adjunct for multi-food allergy
Omalizumab, an anti-IgE monoclonal antibody, received FDA approval in February 2024 as the first medication indicated specifically to reduce the severity of allergic reactions after accidental exposure in patients 1 year of age and older with 1 or more IgE-mediated food allergies, based on the NIAID-funded OUtMATCH trial, in which 67% of participants receiving omalizumab reached the primary tolerability endpoint versus 7% on placebo.[9] Patients using omalizumab for this indication must continue to strictly avoid all of their known food allergens — it raises the threshold for an accidental exposure, it does not permit deliberate consumption of the allergen.[9]
A genuinely Canada-specific regulatory point: omalizumab has long been Health Canada-approved for other indications (moderate-to-severe allergic asthma, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps), but as of the most recent information available, the food-allergy indication specifically has not yet received separate Health Canada approval — Canadian patients cannot currently access it through the standard approved-product pathway for this specific use, an important expectation to set clearly in counseling.
The anaphylaxis action plan and epinephrine autoinjector counseling
Every patient with a confirmed food allergy needs a prescribed epinephrine autoinjector, a written, personalized action plan, and hands-on training in its use — see the Anaphylaxis chapter for the complete weight-based dosing, administration technique, and acute-treatment protocol, which is not repeated here. This chapter's focus is the day-to-day counseling that keeps that plan effective between reactions:
- Carry 2 autoinjectors at all times, not 1 — a single dose can be insufficient, or a device can be used incorrectly on the first attempt, and a working second device needs to be immediately available.
- Track the expiry date proactively (a calendar or app reminder works well) and refill before it lapses; an expired device delivers a reduced and unreliable dose and should not be relied upon in an emergency.
- Know when a second dose is needed — no improvement, or worsening, within 5-15 minutes of the first dose — and when emergency assessment is needed regardless of how well symptoms responded, given the real possibility of a biphasic reaction; both are detailed fully in the Anaphylaxis chapter.
- Practice technique regularly using a trainer device, and make sure it is not only the patient but every regular caregiver, household member, and — for a child — school staff who can demonstrate correct use, not just describe it.
Non-Pharmacologic Treatment
School accommodation
A written, individualized care plan on file at school, staff trained in recognizing a reaction and administering epinephrine, and clear communication with the family about ingredient policies for classroom food events are the practical minimum. Several Canadian provinces have legislated school anaphylaxis policies — Ontario's Sabrina's Law (2005) was the first, requiring schools to maintain individualized plans for students at risk of a life-threatening reaction — reflecting how seriously this is treated as a matter of student safety, not just family preference.
Workplace accommodation
Encourage a patient to disclose their allergy to a manager or trusted colleague to whatever extent they are comfortable with, keep epinephrine on their person or immediately accessible at their workstation rather than stored away, and know the location of the nearest emergency care. For a higher-risk employee, a coworker trained in recognizing a reaction and administering epinephrine adds a meaningful layer of safety, particularly in a workplace with shared food (cafeterias, catered meetings, communal kitchens).
Travel counseling
- Notify the airline of the allergy in advance where relevant, and carry — never check — epinephrine and any other rescue medication.
- Carry a copy of the prescription or a doctor's letter, and safe snacks for situations where suitable food is not readily available.
- Research food-labelling conventions at the destination before travelling — allergen-labelling regulations vary meaningfully by country, and a "may contain"-style statement (or its absence) does not carry the same meaning everywhere as it does under the Canadian framework described above.
- Consider an allergy translation card for the destination language, and medical-alert identification (bracelet or wallet card) at all times, not only while travelling.
Dining out and food preparation
- Communicate clearly and specifically with restaurant staff — naming the allergen and explaining that a reaction can be life-threatening, not simply saying "I don't like" or understating the risk, meaningfully changes how seriously kitchen staff treat the request.
- Ask directly about shared fryers, grills, and prep surfaces, and about ingredient substitutions in sauces, marinades, and garnishes, where allergens are most often hidden.
- Favour restaurants and settings that can answer these questions confidently; be more cautious around buffets, self-serve stations, and bulk bins, where cross-contact is genuinely harder to control.
- At home, use dedicated cutting boards, utensils, and cookware for allergen-free preparation where practical, and wash hands and surfaces thoroughly between handling an allergen-containing food and an allergen-free one.
Nutrition and psychosocial support
Involve a registered dietitian for any patient avoiding milk, wheat, or multiple foods, to confirm the avoidance diet remains nutritionally adequate — this matters most in a growing child. Avoid recommending elimination of any additional food "just in case" without a confirmed allergy: unnecessary restriction carries its own real nutritional and quality-of-life costs and can complicate a future oral food challenge. Actively screen for food-allergy-specific anxiety in patients and caregivers, and point families toward practical peer-support resources (e.g., Food Allergy Canada) for the day-to-day realities of living with the condition that a clinical visit alone cannot fully address.
Special Populations
Infants and young children
Milk, egg, soy, and wheat allergy are commonly outgrown in this age group (see Recognize the Condition), which makes periodic reassessment — rather than indefinite, unquestioned avoidance — an important part of ongoing care. Current Canadian guidance emphasizes that regular ongoing ingestion of an allergenic food, once it has been introduced and is tolerated, appears to help build and maintain tolerance; introduction alone, without regularity afterward, is not enough.[5]
Adolescents and young adults
This age group carries a disproportionate share of severe and fatal food-allergy reactions, driven largely by behaviour rather than a different underlying biology: inconsistent epinephrine-carrying, risk-taking around unfamiliar or unlabelled food, reluctance to disclose the allergy to peers, and alcohol use, which can both blunt early symptom recognition and impair judgment about when to act.[6] Counseling should explicitly normalize carrying epinephrine at this age, discuss practical peer-disclosure strategies, and address alcohol directly rather than assuming it will come up on its own.
Pregnancy and breastfeeding
Current evidence does not support maternal elimination of allergenic foods during pregnancy or breastfeeding as a strategy to prevent food allergy in the infant.[1] For a pregnant patient with her own known food allergy, management is unchanged: continue strict avoidance and epinephrine access exactly as before pregnancy — epinephrine is not contraindicated in pregnancy (see the Anaphylaxis chapter for complete detail).
Multiple food allergies, or food allergy plus asthma
This combination defines a genuinely higher-risk patient group (see Red Flags & Referral) and warrants a correspondingly more intensive action plan: closer and more frequent allergist follow-up, particular attention to optimizing asthma control as a modifiable part of overall risk, and a lower threshold to discuss omalizumab, which was specifically studied in — and is indicated for — patients with more than 1 confirmed IgE-mediated food allergy.[9] Multiple, compounding allergens also add real logistical complexity to school, workplace, and travel accommodation planning, which deserves specific attention rather than being treated as a simple multiple of single-allergen planning.
Monitoring & Follow-Up
- Reassess periodically for natural resolution, particularly for milk, egg, soy, or wheat allergy in a child — through an updated history, consideration of repeat skin testing or specific IgE trending over time, and a supervised oral food challenge when the overall picture supports it (see Assessment & Diagnosis).[4]
- Check epinephrine autoinjector expiry at every relevant visit, and reissue the prescription and action plan whenever a child's weight crosses a dosing threshold.
- For a patient on OIT: monitor adherence to maintenance dosing and for reactions at home, and involve the treating allergist before resuming after any missed or interrupted dose — resuming at the prior maintenance dose without guidance is not automatically safe.[8]
- For a patient on omalizumab: ongoing monitoring per the treating allergist/immunologist's protocol, with continued avoidance counseling reinforced at every visit.
- Revisit and update label-reading education at intervals, not only at diagnosis — regulations, products, and formulations all change over time, and a single early counseling session does not stay current indefinitely.
- Watch for the emergence of new food allergies or additional atopic disease (asthma, eczema, allergic rhinitis, eosinophilic esophagitis) over time, and adjust the overall risk stratification and action plan accordingly.
Common Errors to Avoid
- Diagnosing food allergy from a positive skin prick test or specific IgE alone, without a supporting clinical history or oral food challenge confirmation — a leading driver of unnecessary, sometimes harmful, elimination diets.[1]
- Ordering unvalidated food-specific IgG testing or a broad allergen "panel" to diagnose a food allergy — neither has supporting evidence, and both drive false diagnoses.[7]
- Assuming a food is safe simply because its label carries no "may contain" statement — that statement is voluntary in Canada, so its absence is not a guarantee against cross-contact.[3]
- Assuming a patient's next reaction will mirror the severity of their last one — reaction severity is not reliably predictable from prior history, so full emergency preparedness applies regardless of how mild past reactions have been.[6]
- Prescribing only a single epinephrine autoinjector instead of 2.
- Confusing cross-contact (physical transfer of allergen protein) with cross-reactivity (an immunologic reaction to a related protein) — the correct counseling differs for each (see Choose Initial Treatment).
- Recommending broad, "just in case" elimination of additional foods without a confirmed allergy — unnecessary restriction carries real nutritional and quality-of-life costs and can complicate a future oral food challenge.
- Treating oral immunotherapy or omalizumab as a cure that removes the need for avoidance, an action plan, or epinephrine access — both are adjuncts that raise the reaction threshold, not replacements for any of these.[8][9]
- Letting a single early counseling session on label-reading stand for the life of the allergy — regulations, products, and formulations change, and reinforcement needs to be periodic.
- Overlooking multiple food allergies, or food allergy coexisting with asthma, as a marker of higher risk needing a more intensive action plan.[6]
Clinical Decision Algorithm
Drug Tables
How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.
Anaphylaxis Rescue
The only treatment that reverses anaphylaxis from any food exposure. See the Anaphylaxis chapter for the complete weight-based dosing and repeat-dosing protocol — not duplicated here.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Epinephrine | Anaphylaxis, any food exposure: IM, anterolateral thigh — see the Anaphylaxis chapter for weight-based dosing | Transient tremor, pallor, anxiety, palpitations at standard IM dosing | Caution (not a reason to withhold) with a concurrent beta-blocker | Every patient with a confirmed food allergy needs 2 autoinjectors, not 1, and routine expiry tracking. |
Mild-Reaction Adjuncts (No Anaphylaxis Criteria Met)
For cutaneous-only symptoms after a food exposure. Never a substitute for epinephrine once any anaphylaxis criterion is met — see the Anaphylaxis chapter.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Cetirizine | Adult: 10 mg PO once Pediatric: Weight-/age-based dosing per product monograph | Mild sedation, headache | Minimal — few clinically significant interactions | Preferred over a 1st-generation agent for daytime use. |
| Diphenhydramine | Adult: 25-50 mg PO or IM Pediatric: 1 mg/kg, max 50 mg | Sedation, anticholinergic effects | Additive sedation with other CNS depressants | Sedation can mask a worsening level of consciousness — reassess frequently if used. |
Emerging Disease-Modifying Options — Allergist-Directed Only
Adjuncts that raise the reaction threshold; neither replaces avoidance, the written action plan, or epinephrine access. See Choose Initial Treatment for full detail on patient selection and expected outcomes.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Oral immunotherapy (the culprit food itself) | Build-up phase: Dose increased at supervised in-clinic visits, typically every 1-2 weeks Maintenance phase: Fixed daily dose at home, generally indefinitely | Oral/GI itching, abdominal pain during updosing; risk of anaphylaxis at any point in the protocol, including maintenance | None specific to the food itself | Achieves desensitization reliably; does not guarantee lasting remission off dosing. Only appropriate within a supervised allergy program with resuscitation capability. |
| Omalizumab | Dosing: Weight- and IgE-based subcutaneous dosing per product monograph and the OUtMATCH trial protocol | Injection-site reaction, rare anaphylaxis | Avoid live vaccines during treatment | FDA-approved (2024) to reduce reaction severity after accidental exposure in confirmed multi-food IgE-mediated allergy; not yet Health Canada-approved for this specific indication as of the most recent information available; does not permit deliberate allergen consumption. |
References
- Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management — Journal of Allergy and Clinical Immunology (Sicherer SH, Sampson HA). J Allergy Clin Immunol 2018;141(1):41-58
- Overall prevalence of self-reported food allergy in Canada — Journal of Allergy and Clinical Immunology (Soller L, Ben-Shoshan M, Harrington DW, et al.). J Allergy Clin Immunol 2012;130(4):986-988
- Food Allergen Labelling — Health Canada, Government of Canada. Health Canada, Food Allergen Labelling
- The Natural History and Risk Factors for the Development of Food Allergies in Children and Adults — Current Allergy and Asthma Reports (Lee ECK, Trogen B, Brady K, Ford LS, Wang J). Curr Allergy Asthma Rep 2024;24(3):121-131
- Early introduction is not enough: CSACI statement on the importance of ongoing regular ingestion as a means of food allergy prevention — Allergy, Asthma & Clinical Immunology (Abrams EM, Ben-Shoshan M, Protudjer JLP, Lavine E, Chan ES). Allergy Asthma Clin Immunol 2023;19:63
- Risk factors for severe reactions in food allergy: Rapid evidence review with meta-analysis — Allergy (Turner PJ, Arasi S, Ballmer-Weber B, et al.). Allergy 2022;77(9):2634-2652
- Canadian Society of Allergy and Clinical Immunology position statement: panel testing for food allergies — Allergy, Asthma & Clinical Immunology (Al Ghamdi A, Abrams EM, Carr S, et al.). Allergy Asthma Clin Immunol 2024;20:61
- CSACI guidelines for the ethical, evidence-based and patient-oriented clinical practice of oral immunotherapy in IgE-mediated food allergy — Allergy, Asthma & Clinical Immunology (Begin P, Chan ES, Kim H, et al.). Allergy Asthma Clin Immunol 2020;16:20
- Omalizumab for the Treatment of Multiple Food Allergies — New England Journal of Medicine (Wood RA, Togias A, Sicherer SH, et al.). N Engl J Med 2024;390(10):889-899
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.